Sugi Predict

Sugi Predict / Compounds / SCHEMBL1647387

SCHEMBL1647387

SCHEMBL1647387

CC(C)NC(=O)C(=O)c1c(-c2ccccc2)cc2ccccn12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.70
▸ L3MBTL1 Q9Y468 6/20 0.66
▸ SMN1; SMN2 Q16637 5/20 0.63
▸ MAPT P10636 9/20 0.62
▸ HTT P42858 4/20 0.62
▸ ALDH1A1 P00352 8/20 0.53
▸ LMNA P02545 3/20 0.53
▸ TDP1 Q9NUW8 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ RECQL P46063 1/20 0.46
▸ RAB9A P51151 3/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPK1 P28482 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3891512 0.88 THRB (0.56) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL1645686 0.85 THRB (0.74) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL27817389 0.85 THRB (0.63) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL27836734 0.82 THRB (0.60) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL1645318 0.82 THRB (1.00) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL1647287 0.82 THRB (0.70) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL1644750 0.82 L3MBTL1 (0.69) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL1646718 0.81 THRB (0.61) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL27836749 0.81 SMN1; SMN2 (0.68) THRBL3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL1646729 0.80 THRB (0.60) THRBL3MBTL1SMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 — — US claimed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US claimed
CN-102105170-A Antifungal combination therapy F2G LTD 2011-06-22 — — CN claimed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 — — EP claimed
CN-101679410-A 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD 2010-03-24 — — CN claimed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US claimed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 — — WO claimed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 — — EP claimed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 — — US claimed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 — — US disclosed
CN-101679410-B 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD 2013-11-27 — — CN disclosed
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 — — US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US disclosed
CN-102105170-A Antifungal combination therapy F2G LTD 2011-06-22 — — CN disclosed
US-20050209282-A1 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2005-09-22 — — US disclosed
WO-2005042497-A2 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS, INCORPORATED (US) 2005-05-12 — — WO disclosed
CN-1089253-A The hydroquinone derivatives that replaces CIBA GEIGY AG (CH) 1994-07-13 — — CN disclosed
CN-1019578-B The preparation method of quinoline carboxylic acid derivative KANEBO LTD (JP) 1992-12-23 — — CN disclosed
CN-88101987-A Quinoline carboxylic acid derivative and the antiseptic-germicide that contains them — 1988-11-09 — — CN disclosed
EP-0185961-A2 1-Phenyl-imidazole-5-carboxylic acid derivatives, process for their preparation and their use as growth regulators HOECHST AKTIENGESELLSCHAFT (DE) 1986-07-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209282-A1 Benzimidazoles useful as modulators of ion channels KCNJ11, KCNJ1, KCNJ2 THRB 2598/4885L3MBTL1 3164/4885SMN1; SMN2 1649/4885
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 THRB 2955/4885L3MBTL1 3386/4885SMN1; SMN2 3501/4885
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 THRB 3738/4885L3MBTL1 4094/4885SMN1; SMN2 3682/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 THRB 3788/4885L3MBTL1 1723/4885SMN1; SMN2 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.